TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study on Performance and Safety of Sentinox in the Prevention of Acute Respiratory Infections (ARI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ICF signed.~2. Males and females aged ≥ 18 years and \<64 years at the time of the signature of the ICF.~3. Subjects who are willing to comply with the requirements of the study protocol, attend scheduled visits and calls for the duration of the study by telephone contact and install the Mobile App to use the e-diary.~Exclusion Criteria:~1. Reporting of any symptoms of ARI in the 15 days preceding the Visit 1.~2. Reporting the intake of any drugs, among antiviral or antibacterial therapies, that may interfere with the study results in the 15 days preceding the Visit 1.~3. Presence of any relevant organic, systemic or metabolic disease (particularly significant history of cardiac, renal, neurological, psychiatric, oncology, endocrinology, metabolic or hepatic disease).~4. Immune system illnesses.~5. Known drug and/or alcohol abuse.~6. Individuals who are cognitively impaired and/or who are unable to give informed consent.~7. Ongoing or prior participation in any other clinical trial of an experimental treatment within 30 days from Visit 1.~8. Concurrent or planned treatment with other agents with actual or possible direct antiviral/antibacterial activity.~9. Positive pregnancy test or breastfeeding woman.~10. Known hypersensitivity to the study treatment, its metabolites, or formulation excipient.~11. History of severe drug and / or food allergies.~12. Any condition that, in the opinion of the Investigator, would complicate or compromise the study or well-being of the Subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 63 Years
- Healthy Volunteers: t

Study Arms:
- Group A: treatment with Sentinox performed 3 times/day for 21 days (Type: EXPERIMENTAL): treatment with Investigational Medical Device (IMD) performed 3 times/day for 21 days at 8 am, 2 pm and 8 pm
- Group B:no Sentinox treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* 18 years or older~* Diagnosis of type 1 or type 2 non-insulin dependent diabetes mellitus~* Chronic bilateral pain due to diabetic neuropathy, pain for at least six months.~* Primary pain is located in the feet.~* Subject participated in and completed the XTL 07-001 clinical trial.~Contact site for additional information.~Exclusion Criteria:~* Symptoms of other painful conditions~* Presence of amputations other than toes~* Clinically significant psychiatric or other neuropsychological disorder~* Use of certain medications~* Clinically important other diseases~* Pregnancy~* History of alcohol or narcotic abuse within two years.~Contact site for additional information.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bicifadine 800 mg/day for a year
- 2 (Type: EXPERIMENTAL): Bicifadine 1200 mg/day for a year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: WEANING-Study: Weaning by Early Versus lAte Tracheostomy iN supratentorIal iNtracerebral Bleedings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients requiring intubation / mechanical ventilation~* Supratentorial intracerebral hemorrhage (including:)~* primary spontaneous ICH (lobar / deep)~* ICH related to anticoagulant therapy~* with or without intraventricular hemorrhage~* with or without occlusive and / or communicating hydrocephalus~* Hematoma volume \>0 ml and \<60 ml~* Age 18 - 85 years~* Informed consent (legal representative)~Exclusion Criteria:~* Patients with elective intubation/ventilation for EVD placement~* Patients with do not treat / do not resuscitate orders, severe co- morbidity and life expectancy of less than 3 months~* Absent consent of relatives for invasive (neuro-)critical care~* Contraindication for tracheostomy~* Other than primary supratentorial ICH or supratentorial ICH related to oral anticoagulants~* Pre-existing COPD (known/treated)~* Pre-existing congestive heart failure (≥3 NYHA)~* Pre-existing modified Rankin Scale (≥4)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- early tracheostomy (Type: EXPERIMENTAL): see study description
- late tracheostomy (Type: ACTIVE_COMPARATOR): Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Patient Safety Screening Tool (PSST) for Sepsis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients that are hospitalized in the Neuro Care Unit (NCU)~* Patients that are hospitalized in the Vanderbilt Burn Center~* Patients must be \> 18 years of age~Exclusion Criteria:~* Patients \< 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients in the NCU at VUH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Locally Advanced Esophageal cancer (stages T1N1 or T2-4 any N)~2. Histology must be adenocarcinoma or squamous cell carcinoma~3. Must be surgical candidate based on evaluation by a thoracic surgeon~4. must have adequate organ function as defined by routine lab tests~Exclusion Criteria:~1. Insitu carcinoma~2. prior chemotherapy for esophageal cancer~3. Metastatic (stage IV disease)~4. Tumors \<5cm from the cricopharyngeus muscle, Tumors with \>75% of tumor located within the stomach~5. Active, uncontrolled cardiac disease~6. subjects with \>Grade 2 neuropathies. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Level -1 (Type: EXPERIMENTAL): Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 60mg/m2 cisplatin, 750mg/m2 5FU (Fluorouracil)
- Dose Level 1 (Type: EXPERIMENTAL): Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 80mg/m2 cisplatin, 1000mg/m2 5FU (Fluorouracil)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A 28 Day Parallel Group Study to Assess the Effects of RDN-929

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males or postmenopausal or surgically sterile females age 55 - 85 years old.~* Healthy as determined by the Investigator, based on a medical evaluation including medical history, physical examination, neurological examination, laboratory tests and ECG recording~Exclusion Criteria:~* Any history of major psychiatric disorders, including substance use disorders, according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal (ULN)~* A clinically significant abnormality on physical examination, neurological examination, ECG, or laboratory evaluations~* A clinically significant vital signs abnormality, as judged by the principal investigator

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- RDN-929 (Type: EXPERIMENTAL): low, medium and high dose of RDN-929 capsules
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documentation of cancer.~* The disease may be a solid tumor, Lymphoma or Multiple Myeloma. Pathology reports will be documented in the patient's chart and included in the data.~* Age \> 18 years~* An acute, radiographically confirmed, de novo Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)~* No past medical history of a prior thrombus or known thrombophilia~Exclusion Criteria~* Patients are not eligible for this study if they receive therapeutic doses of any heparin for more than 72 hours before randomization 31.~* Already receiving oral anticoagulant therapy 31.~* Severe renal impairment, calculated using the Cockcroft-Gault formula, defined as a creatinine clearance \<30 mL/min 31.~* Platelet count of less than 50,000 per cubic millimeter~* Bleeding from the gastrointestinal tract that requires blood transfusion (s), intracranial bleeding or retroperitoneal bleeding.~* An indication for thrombolysis~* Allergy to iodine~* Hereditary thrombophilia~* Pregnancy~* Likelihood of noncompliance~* It is contraindicated to anticoagulate patients with brain metastasis secondary to melanoma, choriocarcinoma, renal cell and medullary thyroid carcinoma. If these patients have a Venous Thromboembolism (VTE), it is standard of care for these patients to have a CT of their head to evaluate if there is metastasis to the brain before they are anticoagulated 38. If these patients do have brain metastasis, they will not be included in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1- Arixtra Alone (Type: EXPERIMENTAL): Arixtra Alone
- 2 Arixtra+ filter (Type: ACTIVE_COMPARATOR): Arixtra + filter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with chronic subdural hematoma that needs surgical evacuation~2. Age \> 18 year~Exclusion Criteria:~1. Lack of compliance~2. Kidney artery stenosis~3. Stenosis of the aorta~4. Severely decreased kidney function~5. Allergy or intolerance/contraindications toward ACE inhibitors~6. Already in ACE inhibitor treatment~7. Coagulopathies~8. Malignant disorders~9. Fertile women~10. Other neurological disorders~11. Treatment with pharmaceuticals contraindicating treatment with ACE inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACE inhibitor (Type: ACTIVE_COMPARATOR): patients randomized to this arm will be treated with ACE inhibitors after surgery
- Placebo (Type: PLACEBO_COMPARATOR): patients randomized to this arm will be treated with placebo after surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Cost Effectiveness of Preoperative and Postoperative Cryotherapy in Proximal Tibia Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Skeletally mature~* Trauma patients with single-system musculoskeletal injuries.~* Proximal tibia fractures treated with open reduction and internal fixation.~* Unilateral proximal tibial injuries.~Exclusion Criteria:~* Previous ipsilateral knee surgery~* Upper extremity injuries impairing mobilization~* Pre-existing ipsilateral neurologic condition or acute ipsilateral neurologic injury~* Associated injuries impairing mobilization~* Suspected or confirmed compartment syndrome~* Open fractures~* Patients previously on narcotics~* Patients with impaired sensorium Concurrent head injury Intoxication

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 21 degree Cooling (Type: PLACEBO_COMPARATOR): Room temperature water circulated through cryotherapy sleeve.
- 10 degree cooling (Type: ACTIVE_COMPARATOR): Cooled water circulated through a cryotherapy sleeve.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent as documented by signature (Appendix Informed Consent Form)~* Male and Female patients ≥18 years of age~* Patients with HCC according to imaging findings and/or histology and scheduled for TACE or TARE~Exclusion Criteria:~* Women who are pregnant or breast feeding,~* Please note that female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,~* Previous enrolment into the current study,~* Patients with impaired renal function (estimated glomerular filtration rate \<30 ml/min)~* Patients with non-MRI compatible metallic or electronic implants, devices or metallic foreign bodies (cardiac pacemaker, shrapnel, cochlea implants, neurostimulator, or other non-MRI compatible implants).~* Tumor-directed therapy (i.e. systemic chemotherapy) between transarterial therapy and 3-months follow-up MRI exam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- post-TAE (Type: None): None
- post-TARE (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed soft tissue sarcoma that is unlikely to respond to existing therapy, including surgery, radiotherapy, and chemotherapy~  * Evidence of tumor by MRI, CT scan, chest x-ray, or radionuclide scan~PATIENT CHARACTERISTICS:~Age:~* 6 months and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* No renal insufficiency~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No active infection~* No nonmalignant systemic disease~* Not high medical or psychiatric risk~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since immunotherapy~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplastons~* No other concurrent antineoplastic agents

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients with idiopathic Parkinson Syndrome~* 18 to 85 years~* Nocturnal Pollakisuria \> 2 mictions /night (documented in Screening phase )~* Na+ i.S \> 135 mmol/l~* Patient is able to understand all aspects and individual consequences of the clinical trial~* An informed consent signed and dated by the patient is available prior to any study specific treatment~* The study is consistent with the patients´ request for an appropriate treatment~Exclusion Criteria:~* Intake of the following concomitant medication: Carbamazepin, Oxcarbazepine, diuretics (Furosemide, Torasemide), non steroidal antiphlogistics, Loperamide, antidiuretic hormone analoga (besides study medication), drugs for treatment of bladder disfunction, in particular anticholinergics~* Central Diabetes insipidus~* Known heart insufficiency (NYHA Stad. III und IV)~* clinical relevant kidney insufficiency~* Habitual and psychogenic Polydipsia~* Hypersensitivity or allergy against the trial medication or any other ingredient of the trial medication~* Participation in another clinical trial during or within 6 months prior to this clinical trial~* Medical or psychological condition, which might endanger the proper conduction of the clinical trial~* Known drug or alcohol abuse

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Desmopressin (Type: EXPERIMENTAL): Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male \> 18 years~* carcinoma of the prostate histologically confirmed~* OMS 0-1~* localized stage~* favorable, intermediate and unfavorable groups according to NCCN or D'Amico classification~* patients must have signed a written informed consent form~* patients must be affiliated to a Social Health Insurance.~Exclusion Criteria:~* metastasis~* indication for pelvic radiation~* anticoagulant therapy~* lateral or bilateral hip replacement~* patient receiving an adult protective services~* Patient unable to comply with the required medical follow-up for geographic, social or psychological reasons

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CBCT (Type: OTHER): cone beam computed tomography (CBCT) repositioning
- fiducial markers (Type: OTHER): kV imaging of fiducial marker repositioning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility